(Q37831903)

English

Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms.

scientific article published on 24 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

0 references

0 references

1 reference

based on heuristic

inferred from title

mast cell leukemia

1 reference

based on heuristic

inferred from title

systemic mastocytosis

1 reference

based on heuristic

inferred from title

aggressive systemic mastocytosis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Karl Sotlar

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Hans-Peter Horny

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

24 January 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

52

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

740-744

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Use of monoclonal antibody KP1 for identifying normal and neoplastic human mast cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Mast cells and mast cell neoplasia: a review

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Classification and diagnosis of mastocytosis: current status

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Diagnostic criteria and classification of mastocytosis: a consensus proposal

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Variable expression of activation-linked surface antigens on human mast cells in health and disease

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

CD30 in normal and neoplastic cells.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Tumor necrosis factor receptor superfamily members and their ligands

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.550072

21 January 2018

Identifiers

10.3109/10428194.2010.550072

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21261503%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37831903&oldid=1528567253"